II. Risk 9. Capital Budgeting and
risk premium on the Swiss market index is 6 percent.
13
Then Roche needs to dis-
count the Swiss franc cash flows from its project at 1.1 ⫻ 6 ⫽ 6.6 percent above the
Swiss franc interest rate.
That’s straightforward. But now suppose that Roche considers construction of a
plant in the United States. Once again the financial manager measures the risk of
this investment by its beta relative to the Swiss market index. But notice that the
value of Roche’s business in the United States is likely to be much less closely tied
to fluctuations in the Swiss market. So the beta of the U.S. project relative to the
Swiss market is likely to be less than 1.1. How much less? One useful guide is the
U.S. pharmaceutical industry beta calculated relative to the Swiss market index. It
turns out that this beta has been .36.
14
If the expected risk premium on the Swiss
market index is 6 percent, Roche should be discounting the Swiss franc cash flows
from its U.S. project at .36 ⫻ 6 ⫽ 2.2 percent above the Swiss franc interest rate.
Why does Roche’s manager measure the beta of its investments relative to the
Swiss index, whereas her U.S. counterpart measures the beta relative to the U.S.
index? The answer lies in Section 7.4, where we explained that risk cannot be con-
sidered in isolation; it depends on the other securities in the investor’s portfolio.
Beta measures risk relative to the investor’s portfolio. If U.S. investors already hold
the U.S. market, an additional dollar invested at home is just more of the same.
But, if Swiss investors hold the Swiss market, an investment in the United States
can reduce their risk. That explains why an investment in the United States is
likely to have lower risk for Roche’s shareholders than it has for shareholders in
Merck or Pfizer. It also explains why Roche’s shareholders are willing to accept
a lower return from such an investment than would the shareholders in the U.S.
companies.
15
When Merck measures risk relative to the U.S. market and Roche measures risk
relative to the Swiss market, their managers are implicitly assuming that the share-
holders simply hold domestic stocks. That’s not a bad approximation, particularly
in the case of the United States.
16
Although investors in the United States can re-
duce their risk by holding an internationally diversified portfolio of shares, they
generally invest only a small proportion of their money overseas. Why they are so
shy is a puzzle.
17
It looks as if they are worried about the costs of investing over-
seas, but we don’t understand what those costs include. Maybe it is more difficult
to figure out which foreign shares to buy. Or perhaps investors are worried that a
CHAPTER 9
Capital Budgeting and Risk 233
13
Figure 7.3 showed that this is the historical risk premium on the Swiss market. The fact that the real-
ized premium has been lower in Switzerland than the United States may be just a coincidence and may
not mean that Swiss investors expected the lower premium. On the other hand, if Swiss firms are gen-
erally less risky, then investors may have been content with a lower premium.
14
This is the beta of the Standard and Poor’s pharmaceutical index calculated relative to the Swiss mar-
ket for the period August 1996 to July 2001.
15
When investors hold efficient portfolios, the expected reward for risk on each stock in the portfolio is
proportional to its beta relative to the portfolio. So, if the Swiss market index is an efficient portfolio for
Swiss investors, then Swiss investors will want Roche to invest in a new plant if the expected reward
for risk is proportional to its beta relative to the Swiss market index.
16
But it can be a bad assumption elsewhere. For small countries with open financial borders—
Luxembourg, for example—a beta calculated relative to the local market has little value. Few in-
vestors in Luxembourg hold only local stocks.
17
For an explanation of the cost of capital for international investments when there are costs to interna-
tional diversification, see I. A. Cooper and E. Kaplanis, “Home Bias in Equity Portfolios and the Cost of
Capital for Multinational Firms,” Journal of Applied Corporate Finance 8 (Fall 1995), pp. 95–102.